All In Biotech

Drug Trial Radar · NCT04134845

A Clinical Trial Utilizing Dantrolene in Patients With Ventricular Arrhythmias.

A Randomized Controlled Trial of RyR2 Inhibition With Dantrolene and Susceptibility to Ventricular Arrhythmias in Patients With Structural Heart Disease.

Last checked: Nov 19, 2026Latest source record: Oct 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

68

Actual

Start

Aug 21, 2020

Primary completion

May 29, 2025

Study completion Aug 29, 2025

Sponsor

Lead sponsor
Vanderbilt University Medical CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 22, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, placebo-controlled trial of Dantrolene (N= 84 participants) to demonstrate the feasibility of using intravenous (IV) dantrolene to study the effect of RyR2 inhibition on cardiac electrophysiology, hemodynamics, and ventricular arrhythmia inducibility in patients with structural heart disease referred for Ventricular Tachycardia (VT) ablation. The investigators will also explore the pharmacokinetic/pharmacodynamic relationship of IV dantrolene and its short-term effect on specific cardiac electrophysiologic and hemodynamic parameters.

Conditions

  • Ventricular Tachycardia

Interventions

  • Dantrolene/RyanodexDrug

    muscle relaxant

  • PlaceboDrug

    Controlled placebo of saline administered Intravenous; 1 mg/kg IV over 3 minutes, one time dose

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Inducible Sustained Ventricular Tachycardia/ Ventricular Fibrillation (VT/VF) Utilizing Standardized Stimulation Protocol.Time frame: 10 minutes post drug infusion

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Vanderbilt University Medical Center

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.